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Summary A 36-year-old female patient known to have Marfan syndrome (MFS) presented with
Stanford type B aortic dissection (type B-AD) 3 days after delivery although she had taken oral
-blocker and underwent prophylactic cesarean section at 34 weeks when she showed 42mm of
the ascending aorta. She was successfully treated medically without further progression of the
dissection. A review of the literature revealed an additional 19 patients with MFS who suffered-blocker from type B-AD associated with pregnancy. Of 20 patients, 1 (5%) died but the remaining 19
patients were successfully treated either medically (n = 9) or surgically (n = 10). Of 13 patients
whose aortic diameter was known, 5 showed <40mm of the ascending aorta. Pregnancy in MFS
can be complicated by type B-AD with a peak around term delivery irrespective of the size of
ascending aorta and even with -blocker.
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ntroductionregnancy itself has been associated with an increased risk
f aortic dissection [1] because of increasing cardiac out-
ut as well as blood volume or hormonal changes that could
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irectly weaken the aortic wall [2]. Therefore pregnancy in
emale patients with Marfan syndrome (MFS) may carry a
igher risk of aortic dissection [3]. In general, these aortic
issections occur predominantly at the ascending aorta and
nly rarely at the descending aorta. Therefore a guideline
or management of pregnancy and delivery in patients with
FS was developed according to the size of the ascending
orta [4—6]. We describe a patient with MFS who suffered
rom the Stanford type B aortic dissection (type B-AD) 3
ays after delivery and conducted a review of the literature
Published by Elsevier Ireland Ltd. All rights reserved.
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Table 1 Reported type B aortic dissection associated with pregnancy in patients with Marfan syndrome.
Timing of Ao
dissection
(Weeks)
# of
patients
Known
MFS
Maternal
age (years)
# of
pregnancies
median
(range)
Pre-Ao size
>40mm
Beta
blocker
Tx of Ao
dissection
Maternal
mortality
Fetal or
neonatal
mortality
<GA 34
[3,8—13]
7 7/7 30.2± 3.7 1 (1—6) 4/6 1/6 Medical
5/Surgical 2
1/7 3/7
GA 34—40
[1,14—18]
6 5/5 29.3± 1.5 1.5 (1—3) 1/2 1/5 Medical
2/Surgical 4
0/6 1/6
Delivery — PDW 7 6/7 33.6± 4.2 1 (1—6) 3/5 2/5 Medical 0/7 0/4
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Ao, aortic; GA, gestational age; MFS, Marfan syndrome; PDW, po
before dissection; Tx, treatment; #, number.
to characterize patients’ demographics and management,
and maternal and fetal prognosis in patients with MFS who
suffered from type B-AD associated with pregnancy.
Case report
A 36-year-old female patient, who was known to have MFS
and had been placed on oral atenolol, presented with acute
back pain 3 days after prophylactic cesarean section.
At 10 years of age when she suffered from decreased
visual acuity because of lens dislocation, she visited us and
was diagnosed as having MFS based on Ghent criteria [7]. At
32 years of age when she was conﬁrmed to have ﬁbrillin-1
mutation, 4538 del C, with measured aortic sinus diame-
ter of 40.7mm, she started taking 25mg of atenolol daily,
but could not increase the dosage because of fainting. At
35 years of age, she became married and X-ray computed
tomography showed annuloaortic ectasia without any aor-
tic aneurysm or dissection. After multi-disciplinary meeting,
she expressed strong will to have a child and became preg-
nant 8 months later.
During pregnancy and after delivery, she continued taking
25mg of atenolol and visited us and her obstetrician regu-
larly without any problems. At 34 weeks of gestation, her
aortic sinus diameter was measured as 42mm, interpreted
as a substantial increase from 40.7mm by echocardiography,
and she was scheduled to have elective cesarean section,
according to the Japanese guideline of delivery manage-
ment [4]. She underwent successful cesarean section under
general anesthesia combined with epidural anesthesia for
post-delivery pain control. Her blood pressure was con-
trolled around 115—120mmHg in systole during the delivery.
She resumed taking atenolol next day and had been
hemodynamically stable with systolic blood pressure of
106—117mmHg. Post-delivery day 3, however, she suddenly
complained of back pain when her blood pressure was
measured as 134/60mmHg and emergency X-ray computed
tomography revealed type B-AD starting at the left subcla-
vian artery and ending at the right common iliac artery. She
was transferred to the cardiac care unit and treated medi-
cally with continuous infusion of nitroglycerin to control her
blood pressure and fortunately did not develop any signs
of malperfusion or further dilation of the aorta. Her med-
ication was gradually replaced with combinations of oral
anti-hypertensive drugs and X-ray computed tomography on
M
p
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A2/Surgical 5
livery weeks, Pre-Ao size, the diameter of the ascending aorta
5 days of illness revealed no progressive dilation of the
orta. She was discharged on 34 days of illness with anti-
ypertensive medication and she did not show progression
f the disease at her ﬁnal visit 3 months after the onset of
issection.
A baby girl, without any suspicious signs of MFS, was born
ith Apgar score of 7 and 8 at 1 and 5min, respectively.
he suffered from transient tachypnea that was successfully
reated with nasal positive airway pressure.
eview of the literature
ystematic review of the literature (keywords: Marfan
yndrome; descending aortic aneurysm; pregnancy) was
onducted via PubMed with careful manual review of the
eferences from relevant articles. We identiﬁed 18 rele-
ant articles including a total of an additional 19 patients
ith MFS whose pregnancy was complicated by type B-AD
etween 1983 and 2008 (Table 1) [3,8—22].
The mean age at pregnancy was 30.9± 3.6 (mean and
tandard deviation) years with median 1 (1—6) in gravida.
he number of patients suffered from type B-AD increased
ith gestational age with a peak around term delivery
Table 1). Of 20 patients, 1 (5%) patient presented at 17
eeks and died, despite prophylactic aortic root replace-
ent. The remaining 19 patients were successfully treated
ither medically (n = 9) or surgically (n = 10). Although
7 patients were known to have MFS, only 4 patients
ere placed on oral -blocker. Of 13 patients whose size
f ascending aorta was determined during pregnancy, 5
atients (38%) showed <40mmof the size of ascending aorta.
iscussion
his study indicates that pregnancy with MFS can be
omplicated by type B-AD with a peak around term deliv-
ry irrespective of the size of ascending aorta and even
ith -blocker and prophylactic cesarean section and
ighlights several issues associated with pregnancy with
FS.
The ﬁrst issue is the timing of type B-AD associated with
regnancy in MFS. We must keep in mind that type B-AD
ay occur at any time during pregnancy or after delivery.
lthough the incidence of type B-AD increased with gesta-
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ional age as shown in Table 1, wemust realize that one third
f type B-AD occurred after delivery. In fact, our patient
eveloped type B-AD even after premature cesarean sec-
ion at 34 weeks. Therefore, we have to prepare for sudden
nset of this complication at any time and let all medical
ersonnel know it.
The second issue is to predict this type of B-AD associ-
ted with pregnancy. Although several guidelines have been
ublished from different associations, all these guidelines
ere based on the size of ascending aorta to prevent ascend-
ng aortic dissection and there was no guideline to predict
ype B-AD [4—6]. Substantially the size of the ascending
orta cannot be a predictor of type B-AD. In our patient, we
ffered prophylactic cesarean section to prevent ascending
ortic dissection after we noticed signiﬁcant dilation of the
scending aorta, but she suffered from type B-AD. Further-
ore, about one third (38%) of the patients with type B-AD
howed <40mm of the ascending aorta and were thought
o be relatively safe to undergo pregnancy in MFS. On the
ther hand, we have to emphasize that a patient who under-
ent prophylactic replacement of ascending aorta does have
igniﬁcant risk of developing type B-AD because the spe-
iﬁc patient might have generalized aortic wall disruption
nd carry a higher risk of developing aortic dissection at
ny part of the aorta [19]. Because there were few data
vailable concerning the size of descending aorta prior to
issection in this study, it was impossible to determine the
peciﬁc size of descending aorta to predict dissection asso-
iated with pregnancy, although Engelfriet et al. suggested
hat patients with descending aorta of >20mm carry a higher
isk of descending aortic dissection later on [23].
The third issue is treatment to prevent vascular wall
isruption resulting in aortic dissection in MFS. Since both
ngiotensin-converting enzyme inhibitors and angiotensin
eceptor blockers are known to be teratogenic, theoreti-
ally these drugs cannot be used. Although -blocker is the
ecommended medication during pregnancy with MFS, only
of 16 patients had been placed on -blocker during preg-
ancy and it is impossible to determine the effectiveness of
-blockers in this study. In addition, prophylactic preterm
ermination of pregnancy may not prevent descending aortic
issection. In fact, we terminated pregnancy at 34 weeks,
he earliest gestational age when usually a baby can survive
ithout signiﬁcant respiratory problems, but the patient
eveloped aortic dissection. On the other hand, it must be
etermined if strict control of blood pressure with any med-
cation during pregnancy and after delivery may prevent
escending aortic dissection.
Considering these unsolved issues, the only substantial
ay to prevent type B-AD associated with pregnancy in MFS
ight be to identify patients with MFS as early in life as
e can and place them on therapy to prevent aortic wall
isruption [24,25].
onclusionshis case report and literature review revealed that preg-
ancy in patients with MFS has a signiﬁcant risk of aortic
issection not only at the ascending aorta but also at the
escending aorta even when treated with -blocker. We
ave to accumulate more data to identify any predictor of
[
[H. Nishino et al.
his descending aortic dissection associated with pregnancy.
r, ultimately we have to ﬁnd a way to prevent the remod-
ling of the aortic wall and to minimize aortic dilation in
atients with MFS.
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